Published 19 minutes ago • loading... • Updated 43 minutes ago
Menopause drug made in Canada won't be available to Canadians, but still sold in U.S.
Pfizer said commercial pressures made the menopause drug unsustainable as Health Canada assesses shortages and physicians warn patients may face treatment changes.
Pfizer announced on Thursday it will discontinue Premarin vaginal cream and oral tablets in Canada, citing commercial unsustainability. The cream is pulled immediately while tablets remain available until next June.
Manufacturing costs and the pricing environment drove the decision, according to Pfizer Canada spokesperson Sophie Morin. The active ingredient is produced in Brandon, Manitoba, yet the medication remains available in the United States.
Menopause specialist Dr. Michelle Jacobson criticized the move, noting Canadians lose access to a homegrown product. Gynecologist Dr. Jen Gunter highlighted the price disparity: Premarin costs around $50 in Canada versus $400 to $500 in the United States.
Physicians warn that switching treatments may trigger rebound symptoms or complications like urinary tract infections. Provinces including Ontario are reviewing alternatives such as Estragyn to ensure continued access to hormone therapy.
A spokesperson for federal Health Minister Marjorie Michel said Health Canada is assessing the discontinuation's impact on supply. The decision coincides with a 228-per-cent increase in hormone-replacement therapy claims among women aged 45 to 54, per Manulife Canada.